Could your own immune cells fight lung cancer? new trial tests safety

NCT ID NCT07498439

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test whether infusing a patient's own tumor-fighting immune cells (called TILs) is safe for people with early-stage non-small cell lung cancer that has multiple spots in the lungs. Researchers will collect immune cells from the tumor or lung fluid, grow them in a lab, and give them back to the patient. The main goal is to check for side effects, not yet to see if it works. Fifty adults aged 18 to 75 with confirmed multiple lung nodules will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tumor-infiltrating lymphocytes (TILs) - immune cells taken from the patient's own tumor or lung fluid, grown in a lab, and given back as an infusion

What this could lead to

If this treatment is safe, it could point toward a new way to control early-stage lung cancer using the body's own immune cells.

What could go wrong

This is a very early, small safety study, so it is not designed to prove the treatment works. There may be side effects from the infusion, and the approach may not shrink tumors or prevent cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY EARLY-STAGE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.